Effect of pivaloyl-substituted pyrrole containing heterocyclic compounds on DNA repair pathways in Ewing sarcoma cells
- Authors: Galembikova AR1, Boychuk SV1, Dunaev PD1, Khusnutdinov RR1, Zykova SS2
-
Affiliations:
- Kazan State Medical University
- Perm Penal Service Institute
- Issue: Vol 99, No 2 (2018)
- Pages: 245-248
- Section: Experimental medicine
- URL: https://journal-vniispk.ru/kazanmedj/article/view/8414
- DOI: https://doi.org/10.17816/KMJ2018-245
- ID: 8414
Cite item
Abstract
Aim. To examine deoxyribonucleic acid (DNA) damage repair and cell cycle regulatory mechanisms of Ewing sarcoma cells exposed to pivaloyl-substituted pyrrole containing heterocyclic compounds.
Methods. The study was performed on A673 Ewing sarcoma cell line. The tumor cells were incubated for 48 h in the presence of pivaloyl-substituted pyrrole containing heterocyclic compounds (compounds №20 and №24). Western blot analysis was utilized to examine expression of the markers of DNA single-strand (phosphorylated forms of ATR and Chk1) and double-strand breaks (phosphorylated forms of H2AX, АТМ, DNA-PK, BRCA-1, Chk-2). Analysis of the cell cycle phases was performed by flow cytometry (BD FacsCanto, USA).
Results. Pivaloyl-substituted pyrrole containing heterocyclic compounds substantially increased the expression of histone 2A phosphorylated on serine 138 (γ-H2AX) that indicates DNA damage (double-strand breaks). Under exposure to pivaloyl-substituted pyrrole containing heterocyclic compounds the studied cells increased expression of phosphorylated forms of ATM-kinase and BRCA-1. Also cell cycle disorders leading to substantial G2/M arrest and enhanced apoptosis of tumor cells were observed.
Conclusion. Pivaloyl-substituted pyrrole containing heterocyclic compounds induced DNA double-strand breaks in A673 Ewing sarcoma cell line; in response to DNA damage in tumor cells, the mechanisms of DNA double-strand breaks repair were activated; despite activation of DNA repair mechanisms, A673 cells underwent cell cycle arrest in the G2/M-phase and apoptosis.
Full Text
##article.viewOnOriginalSite##About the authors
A R Galembikova
Kazan State Medical University
Author for correspondence.
Email: boichuksergei@mail.ru
Kazan, Russia
S V Boychuk
Kazan State Medical University
Email: boichuksergei@mail.ru
Kazan, Russia
P D Dunaev
Kazan State Medical University
Email: boichuksergei@mail.ru
Kazan, Russia
R R Khusnutdinov
Kazan State Medical University
Email: boichuksergei@mail.ru
Kazan, Russia
S S Zykova
Perm Penal Service Institute
Email: boichuksergei@mail.ru
Perm, Russia
References
- Delattre O., Zucman J., Melot T. et al. The Ewing-family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N. Engl. J. Med. 1994; 331 (5): 294-299. doi: 10.1056/NEJM199408043310503.
- Le Deley M.C., Delattre O., Schäfer K.L. et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J. Clin. Oncol. 2010; 28 (12): 1982-1988. doi: 10.1200/JCO.2009.23.3585.
- Van Doominck J.A., Ji L., Schaub B. et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 2010; 28 (12): 1989-1994. doi: 10.1200/JCO.2009.24.5845.
- Juergens C., Weston C., Lewis I. et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr. Blood Cancer. 2006; 47 (1): 22-29. doi: 10.1002/pbc.20820.
- Le Deley M.C., Paulussen M., Ian Lewis I. et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J. Clin. Oncol. 2014; 32 (23): 2440-2448. doi: 10.1200/JCO.2013.54.4833.
- Womer R.B., West D.C., Krailo M.D. et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 2012; 30 (33): 4148-4154. doi: 10.1200/JCO.2011.41.5703.
- Wagner L.M., McAllister N., Goldsby R.E. et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr. Blood Cancer. 2007; 48 (2): 132-139. doi: 10.1002/pbc.20697.
- Haeusler J., Ranft A., Boelling T. et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer. 2010; 116 (2): 443-450. doi: 10.1002/cncr.24740.
- Boichuk S., Galembikova A., Zykova S. et al. Ethyl-2-amino-pyrrole-3-carboxylates are novel potent anticancer agents that affect tubulin polymerization, induce G2/M cell-cycle arrest, and effectively inhibit soft tissue cancer cell growth in vitro. Anti-Cancer Drugs. 2016; 27 (7): 620-634. doi: 10.1097/CAD.0000000000000372.
- Kumagai A., Lee J., Yoo H.Y., Dunphy W.G. TopBP1 activates the ATR-ATRIP complex. Cell. 2006; 124 (5): 943-955. doi: 10.1016/j.cell.2005.12.041.
Supplementary files
